Gouty Arthritis (Gout) Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Additionally, the report provides an overview of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects.
Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.
Inquire for Complete PDF Report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1020042
Description of Report:
Gouty Arthritis (Gout) Pipeline Review H1 2017 report reviews therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 11, 2, 16, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive.
Gouty Arthritis (Gout) Key Companies Analysed:
Allena Pharmaceuticals Inc, AstraZeneca Plc, C&C Research Laboratories, Cell Medica Ltd, CymaBay Therapeutics Inc, Genentech Inc, Immune Response BioPharma Inc, Jiangsu Hengrui Medicine Co Ltd, Monosol Rx LLC, Opsona Therapeutics Ltd, Polaris Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, Swedish Orphan Biovitrum AB, Teijin Pharma Ltd, Wellstat Therapeutics Corp, XL-protein GmbH .
Gouty Arthritis Drug Profile Discussed: ALLN-346, anakinra, APP-112, AQB-565, arhalofenate, colchicine, dapansutrile, diacerein, diacerein CR, DLX-2323, DLX-2681, febuxostat, HSA-Uricase, IR-888, Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation, Neurodegenerative Diseases and Respiratory Infections, ND-2110, ND-2158, ND-346, pegadricase, R-191, Recombinant Enzyme for Gout and Tumor Lysis Syndrome, REV-002, RLBN-1001, SHR-4640, Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia, Small Molecules for Gout, Small Molecules to Inhibit GLUT9 for Gout, Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis, TMX-049, URC-102, uriSHELS, VCB-201, verinurad, WT-2107, XEN-102, XL-400
The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout). The report reviews pipeline therapeutics for Gouty Arthritis (Gout) by companies and universities/research institutes based on information derived from company and industry-specific sources. The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities. The report reviews key player’s involved Gouty Arthritis (Gout) therapeutics and enlists all their major and minor projects. The report assesses Gouty Arthritis (Gout) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) advantage.
Major Table OF Content
- Number of Products under Development for Gouty Arthritis (Gout), H1 2017
- Number of Products under Development by Companies, H1 2017
- Number of Products under Development by Universities/Institutes, H1 2017
- Products under Development by Companies, H1 2017
- Products under Development by Universities/Institutes, H1 2017
- Number of Products by Stage and Target, H1 2017
- Number of Products by Stage and Mechanism of Action, H1 2017
- Number of Products by Stage and Route of Administration, H1 2017
- Number of Products by Stage and Molecule Type, H1 2017
- Gouty Arthritis (Gout) - Pipeline by Aphios Corp, H1 2017
- Gouty Arthritis (Gout) - Pipeline by Cannabis Science Inc, H1 2017
- Gouty Arthritis (Gout) - Pipeline by CytRx Corp, H1 2017
- Gouty Arthritis (Gout) - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
- Gouty Arthritis (Gout) - Pipeline by RedHill Biopharma Ltd, H1 2017
- Gouty Arthritis (Gout) - Pipeline by Tumorend LLC, H1 2017
- Gouty Arthritis (Gout) - Pipeline by VasGene Therapeutics Inc, H1 2017
- Gouty Arthritis (Gout) - Dormant Projects, H1 2017
- Gouty Arthritis (Gout) - Dormant Projects, H1 2017 (Contd..1), H1 2017
- Gouty Arthritis (Gout) - Discontinued Products, H1 2017
Direct Purchase This Report @: http://www.reportsnreports.com/purchase.aspx?name=1020042
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441
Reportnreports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 500,000+ industry & country research reports covers 5000+ micro markets. This comprehensive collection of market research reports include market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more..